The risk-associated alleles of the six candidate variants are associated with a decreased risk of overall breast cancer, estrogen receptor (ER) positive breast cancer and breast cancer in BRCA1 mutation carriers but most strongly with ER-negative breast cancer [41]. This evidence concerns the gene ESR1 and breast carcinoma.